BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37546706)

  • 21. [The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia].
    Fei XH; Gu JY; Yin YM; Cheng HY; Zhang WJ; Zhang SQ; Zhao J; Wang JB
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):578-583. PubMed ID: 32397021
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
    Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
    Front Immunol; 2022; 13():934442. PubMed ID: 36110859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
    Hu GH; Zhao XY; Zuo YX; Chang YJ; Suo P; Wu J; Jia YP; Lu AD; Li YC; Wang Y; Jiao SC; Zhang LJ; Kong J; Yan CH; Xu LP; Zhang XH; Liu KY; Cheng YF; Wang Y; Zhang LP; Huang XJ
    Leukemia; 2021 Nov; 35(11):3092-3100. PubMed ID: 33824464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Li MY; Lin ZH; Hu MM; Kang LQ; Wu XX; Chen QW; Kong X; Zhang J; Qiu HY; Wu DP
    Biomark Res; 2020; 8():36. PubMed ID: 32874588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.
    Wang S; Liu A; Wang N; Wang Y; Zhang A; Wang L; Yu W; Li C; Zhang Y; Hu Q
    Front Pediatr; 2022; 10():1100404. PubMed ID: 36727001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Yin Z; Zhang Y; Wang X
    Biomark Res; 2021 Jul; 9(1):58. PubMed ID: 34256851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of CAR-T bridging HSCT in patients with acute CD19
    Ma Y; Zhang S; Fang H; Yu K; Jiang S
    Oncol Lett; 2020 Oct; 20(4):20. PubMed ID: 32774493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unity brings strength: Combination of CAR-T cell therapy and HSCT.
    Huang R; Wang X; Zhang X
    Cancer Lett; 2022 Nov; 549():215721. PubMed ID: 35537573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hamdi A; Mawad R; Bassett R; di Stasi A; Ferro R; Afrough A; Ram R; Dabaja B; Rondon G; Champlin R; Sandmaier BM; Doney K; Bar M; Kebriaei P
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1767-71. PubMed ID: 25017763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
    Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
    Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.
    Ding G; Chen H
    Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
    Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
    BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results.
    Li Z; Yang K; Song Y; Zhao Y; Wu F; Wen X; Li J; Wang X; Xu T; Zheng X; Zheng Q; Wu T
    Front Oncol; 2022; 12():1048296. PubMed ID: 36686744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.
    Kong D; Yang T; Geng J; Jing R; Zhang Q; Wei G; Huang H; Hu Y
    J Zhejiang Univ Sci B; 2022 Oct; 23(10):876-880. PubMed ID: 36226540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.